BR0209204A - Imunoglobulina 1 - Google Patents

Imunoglobulina 1

Info

Publication number
BR0209204A
BR0209204A BR0209204-2A BR0209204A BR0209204A BR 0209204 A BR0209204 A BR 0209204A BR 0209204 A BR0209204 A BR 0209204A BR 0209204 A BR0209204 A BR 0209204A
Authority
BR
Brazil
Prior art keywords
present
producing
immunoglobulin
mammal
relates
Prior art date
Application number
BR0209204-2A
Other languages
English (en)
Inventor
Frank Grosveld
Original Assignee
Univ Erasmus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Erasmus filed Critical Univ Erasmus
Publication of BR0209204A publication Critical patent/BR0209204A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Humanized animals, e.g. knockin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Abstract

"IMUNOGLOBULINA 1". A presente invenção está relacionada com um método para a produção de imunoglobulinas de cadeia simples em um mamífero. Em particular, a presente invenção está relacionada com um método para a produção de anticorpos VHH de camelídeo de cadeia simples em um mamífero que foi submetido ao processo de troca de classe e maturação de afinidade encontrada nas células B que produzem anticorpos. Os anticorpos de cadeia simples produzidos utilizando o método da presente invenção e os seus usos são também descritos.
BR0209204-2A 2001-04-24 2002-04-24 Imunoglobulina 1 BR0209204A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0110029.6A GB0110029D0 (en) 2001-04-24 2001-04-24 Transgenic animal
PCT/IB2002/002424 WO2002085945A2 (en) 2001-04-24 2002-04-24 Vhh single heavy chain antibody and a method for its preparation in a mammal

Publications (1)

Publication Number Publication Date
BR0209204A true BR0209204A (pt) 2004-07-06

Family

ID=9913359

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0209204-2A BR0209204A (pt) 2001-04-24 2002-04-24 Imunoglobulina 1
BR0209207-7A BR0209207A (pt) 2001-04-24 2002-04-24 Imunoglobulina 2

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR0209207-7A BR0209207A (pt) 2001-04-24 2002-04-24 Imunoglobulina 2

Country Status (16)

Country Link
US (6) US20040137570A1 (pt)
EP (2) EP1381630A2 (pt)
JP (3) JP2005503129A (pt)
CN (2) CN1518559A (pt)
AT (1) ATE358730T1 (pt)
AU (1) AU2002256866B2 (pt)
BR (2) BR0209204A (pt)
CA (2) CA2445253C (pt)
CY (1) CY1107669T1 (pt)
DE (1) DE60219321T2 (pt)
DK (1) DK1414858T3 (pt)
ES (1) ES2284863T3 (pt)
GB (1) GB0110029D0 (pt)
MX (2) MXPA03009776A (pt)
PT (1) PT1414858E (pt)
WO (2) WO2002085944A2 (pt)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
ES2368733T3 (es) 2002-07-18 2011-11-21 Merus B.V. Producción recombinante de mezclas de anticuerpos.
GB0228210D0 (en) * 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
GB0230203D0 (en) * 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
EP1592711A1 (en) * 2003-02-06 2005-11-09 Novozymes A/S Human heavy chain antibody expression in filamentous fungi
CA2527694C (en) 2003-05-30 2015-07-14 Hendricus Renerus Jacobus Mattheus Hoogenboom Fab library for the preparation of anti vegf and anti rabies virus fabs
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP1737971B1 (en) 2004-01-20 2017-08-16 Merus N.V. Mixtures of binding proteins
EP1864998B2 (en) * 2004-07-22 2022-06-22 Erasmus University Medical Center Rotterdam Binding molecules
GB2416768A (en) * 2004-07-22 2006-02-08 Univ Erasmus Heavy chain immunoglobulin complexes
WO2006036882A2 (en) * 2004-09-24 2006-04-06 Washington University Methods for determining and lowering caffeine concentration in fluids
FR2879605B1 (fr) 2004-12-16 2008-10-17 Centre Nat Rech Scient Cnrse Production de formats d'anticorps et applications immunologiques de ces formats
GB0522460D0 (en) * 2005-11-03 2005-12-14 Prendergast Patrick T Composition and method for the treatment of avian influenza
GB0618345D0 (en) * 2006-09-18 2006-10-25 Univ Erasmus Binding molecules
JP5184374B2 (ja) 2006-01-25 2013-04-17 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム 対立遺伝子排除
GB0601511D0 (en) * 2006-01-25 2006-03-08 Univ Erasmus Medical Ct Binding Molecules 2
JP5105468B2 (ja) * 2006-12-05 2012-12-26 独立行政法人産業技術総合研究所 細胞内で機能する抗体の創製および細胞表現型を制御するタンパク質の同定
WO2008074839A2 (en) 2006-12-19 2008-06-26 Ablynx N.V. Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
EP2514767A1 (en) 2006-12-19 2012-10-24 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
GB0706628D0 (en) * 2007-04-04 2007-05-16 Univ Erasmus Germ-line manipulation 1
EP2152880B1 (en) 2007-06-01 2011-08-31 Omt, Inc. Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
EP2650311A3 (en) 2007-11-27 2014-06-04 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
WO2009121948A2 (en) 2008-04-03 2009-10-08 Vib Vzw Single domain antibodies capable of modulating bace activity
US9908943B2 (en) 2008-04-03 2018-03-06 Vib Vzw Single domain antibodies capable of modulating BACE activity
GB0809069D0 (en) 2008-05-19 2008-06-25 Univ Leuven Kath Gene signatures
CN102056945A (zh) 2008-04-07 2011-05-11 埃博灵克斯股份有限公司 针对Notch途径的单可变结构域
JP6034023B2 (ja) 2008-05-16 2016-11-30 アブリンクス エン．ヴェー． Ｃｘｃｒ４及び他のｇｐｃｒに指向性を有するアミノ酸配列及びそれを含む化合物
DK2285408T3 (en) 2008-06-05 2019-02-04 Ablynx Nv AMINO ACID SEQUENCES AGAINST COATING PROTEINS IN A VIRUS AND POLYPEPTIDES INCLUDING THESE FOR TREATMENT OF VIRUSAL DISEASES
CN104004094B (zh) * 2008-06-25 2017-09-22 艾斯巴技术-诺华有限责任公司 使用通用抗体构架进行的兔抗体的人源化
US20100136584A1 (en) * 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
US20100092470A1 (en) * 2008-09-22 2010-04-15 Icb International, Inc. Antibodies, analogs and uses thereof
WO2010070145A2 (en) 2008-12-19 2010-06-24 Ablynx N.V. Method for generation of immunoglobulin sequences
CA2749572A1 (en) 2009-01-14 2010-07-22 Iq Therapeutics Bv Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
PT2491056T (pt) 2009-10-22 2021-10-26 Univ Of Twente Vhh para aplicação na reparação de tecidos, regeneração de órgãos, substituição de órgãos e engenharia de tecidos
PT2954779T (pt) * 2009-12-10 2019-05-29 Regeneron Pharma Ratinhos que produzem anticorpos de cadeia pesada
US8962807B2 (en) 2009-12-14 2015-02-24 Ablynx N.V. Single variable domain antibodies against OX40L, constructs and therapeutic use
WO2011083140A1 (en) 2010-01-08 2011-07-14 Ablynx Nv Immunoglobulin single variable domain directed against human cxcr4
EP3095871B1 (en) 2010-02-08 2019-04-10 Regeneron Pharmaceuticals, Inc. Common light chain mouse
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
US8937164B2 (en) 2010-03-26 2015-01-20 Ablynx N.V. Biological materials related to CXCR7
US9556273B2 (en) 2010-03-29 2017-01-31 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
US9101674B2 (en) 2010-03-29 2015-08-11 Vib Vzw Targeting and in vivo imaging of tumor-associated macrophages
GB201014715D0 (en) 2010-09-06 2010-10-20 Vib Vzw Nanobodies stabilizing functional conformational states of GPCRS
NZ707327A (en) 2010-08-02 2017-01-27 Regeneron Pharma Mice that make binding proteins comprising vl domains
PL2609119T3 (pl) 2010-08-26 2018-02-28 Agrosavfe N.V. Białka wiążące chitynowy sacharydowy antygen
KR101832040B1 (ko) 2010-11-08 2018-04-04 노파르티스 아게 Ｃｘｃｒ２ 결합 폴리펩티드
JP6181040B2 (ja) 2011-03-28 2017-08-16 アブリンクス エン．ヴェー． 二特異性抗ｃｘｃｒ７免疫グロブリン単一可変ドメイン
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
PT2723764T (pt) 2011-06-21 2018-03-09 Univ Leland Stanford Junior Domínios de ligação dirigidos contra complexos gpcr:proteína g e suas utilizações derivadas
MY172718A (en) 2011-08-05 2019-12-11 Regeneron Pharma Humanized universal light chain mice
WO2013036130A1 (en) * 2011-09-09 2013-03-14 Universiteit Utrecht Holding B.V. Broadly neutralizing vhh against hiv-1
JP2014531452A (ja) 2011-09-19 2014-11-27 カイマブ・リミテッド 動物、レパートリーおよび方法
ES2906462T3 (es) 2011-10-17 2022-04-18 Regeneron Pharma Ratones de cadena pesada de inmunoglobulina restringida
CN102372779A (zh) * 2011-10-25 2012-03-14 李江伟 具有蒜氨酸酶活性的骆驼单域抗体及制备方法和应用
US10112987B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
US10112988B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
EP2617732A1 (en) 2012-01-19 2013-07-24 Vib Vzw Tools and methods for expression of membrane proteins
CN102660551B (zh) * 2012-02-09 2014-04-16 陈志南 来源于抗CypA骆驼科动物的重链VHH抗体基因、编码多肽及其应用
RU2014141536A (ru) * 2012-03-16 2016-05-10 Регенерон Фармасьютикалз, Инк. Мыши, которые продуцируют антигенсвязывающие белки с зависимыми от величины ph характеристиками связывания
WO2013144567A1 (en) 2012-03-28 2013-10-03 Kymab Limited Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
MX360109B (es) 2012-04-20 2018-10-23 Merus Nv Metodos y medios para la produccion de moleculas de tipo ig.
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
JP6411333B2 (ja) 2012-05-24 2018-10-24 ブイアイビー ブイゼットダブリュＶｉｂ Ｖｚｗ 腫瘍関連マクロファージのターゲティングおよびｉｎｖｉｖｏイメージング用抗マクロファージマンノース受容体単一可変ドメイン
KR102381716B1 (ko) 2012-06-12 2022-04-01 리제너론 파마슈티칼스 인코포레이티드 제한된 면역글로불린 중쇄 유전자좌를 가지는 인간화된 비-인간 동물
EP2931030B2 (en) 2012-12-14 2024-01-17 OmniAb, Inc. Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
CA2899693C (en) 2013-01-30 2023-03-14 Vib Vzw Novel chimeric polypeptides for screening and drug discovery purposes
PT2953973T (pt) 2013-02-05 2019-10-25 Univ Brussel Vrije Agentes de ligação do receptor muscarínico de acetilololina e usos
WO2014130690A1 (en) 2013-02-20 2014-08-28 Regeneron Pharmaceuticals, Inc. Non-human animals with modified immunoglobulin heavy chain sequences
WO2014141192A1 (en) 2013-03-15 2014-09-18 Erasmus University Medical Center Generation of heavy chain-only antibodies
US9617339B2 (en) 2013-03-15 2017-04-11 Vib Vzw Method of imaging a cardiovascular disease with an anti-macrophage mannose receptor immunoglobulin single variable domain
EP2992101B1 (en) * 2013-04-29 2018-10-10 Agrosavfe N.V. Agrochemical compositions comprising antibodies binding to sphingolipids
CN105555303A (zh) 2013-06-28 2016-05-04 贝勒研究院 用于多发性硬化症的树突细胞asgpr靶向免疫治疗剂
CN103454413B (zh) * 2013-09-04 2015-03-11 吉日木图 双峰驼特异性抗体制备及免疫检测方法
WO2015121092A1 (en) 2014-01-30 2015-08-20 Vib Vzw Opioid receptor binding agents and uses thereof
SG11201607203XA (en) 2014-03-21 2016-09-29 Regeneron Pharma Non-human animals that make single domain binding proteins
SG11201607015VA (en) 2014-03-21 2016-09-29 Regeneron Pharma V<sb>L</sb> ANTIGEN BINDING PROTEINS EXHIBITING DISTINCT BINDING CHARACTERISTICS
DK3129400T3 (da) * 2014-04-08 2020-06-08 Regeneron Pharma Ikke-humane dyr med humaniserede Fc-gamma-receptorer
CA2979702A1 (en) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
IL293719B2 (en) 2015-05-21 2023-07-01 Harpoon Therapeutics Inc Trispecific binding proteins and methods of use
CN107849126B (zh) 2015-07-29 2022-04-08 阿勒根公司 仅有重链的抗ang-2抗体
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
WO2017030909A1 (en) 2015-08-14 2017-02-23 Allergan, Inc. Heavy chain only antibodies to pdgf
JP2018535655A (ja) 2015-09-29 2018-12-06 アムジエン・インコーポレーテツド Ａｓｇｒ阻害剤
CN109438573B (zh) * 2015-12-25 2020-11-10 中国农业科学院兰州兽医研究所 猪流行性腹泻病毒m蛋白特异性重链抗体
JP7166923B2 (ja) 2016-02-05 2022-11-08 オリオニス バイオサイエンシズ ビーブイ 標的療法剤およびその使用
JP2019507762A (ja) 2016-03-07 2019-03-22 ブイアイビー ブイゼットダブリュー Ｃｄ２０結合単一ドメイン抗体
CN105777894A (zh) * 2016-03-12 2016-07-20 长春力太生物技术有限公司 通过转基因啮齿类动物制备人源化驼类单域抗体的方法
US11186641B2 (en) 2016-03-17 2021-11-30 Oslo Universitetssykehus Hf Fusion proteins targeting tumour associated macrophages for treating cancer
CN109563141A (zh) 2016-05-13 2019-04-02 奥里尼斯生物科学公司 对非细胞结构的治疗性靶向
US10100106B2 (en) 2016-05-20 2018-10-16 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
AU2017267793B2 (en) 2016-05-20 2024-01-25 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
KR20190052006A (ko) * 2016-08-24 2019-05-15 테네오바이오, 인코포레이티드 변형된 중쇄-단독 항체를 생산하는 형질전환 비-인간 동물
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
MX2019006043A (es) 2016-11-23 2019-09-26 Harpoon Therapeutics Inc Proteína de unión de antígeno prostático específico de membrana.
BR112019010602A2 (pt) 2016-11-23 2019-12-17 Harpoon Therapeutics Inc proteínas trispecíficas para psma e métodos de uso
CN110139952B (zh) * 2016-12-09 2022-11-25 深圳华大生命科学研究院 骆驼科抗体可变区免疫组库构建的引物组合及应用
EP3332637A1 (en) 2016-12-09 2018-06-13 Universitätsklinikum Hamburg-Eppendorf Vhh-containing heavy chain antibody and production thereof
SG11201906540WA (en) 2017-01-19 2019-08-27 Open Monoclonal Tech Inc Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
WO2018141964A1 (en) 2017-02-06 2018-08-09 Orionis Biosciences Nv Targeted chimeric proteins and uses thereof
EP3589662A4 (en) 2017-02-28 2020-12-30 Harpoon Therapeutics, Inc. INDUCTIBLE MONOVALENT ANTIGBINDING PROTEIN
JP7209936B2 (ja) 2017-05-12 2023-01-23 ハープーン セラピューティクス，インク． Ｍｓｌｎ標的三重特異性タンパク質及びその使用方法
KR102376863B1 (ko) 2017-05-12 2022-03-21 하푼 테라퓨틱스, 인크. 메소텔린 결합 단백질
WO2018222587A1 (en) 2017-05-30 2018-12-06 The Regents Of The University Of California NANOBODIES AGAINST CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) INHIBITORY FACTOR (Cif)
CR20200195A (es) 2017-10-13 2020-08-14 Harpoon Therapeutics Inc Proteínas de unión a antigenos de maduraciòn de celulas b
KR102569133B1 (ko) 2017-10-13 2023-08-21 하푼 테라퓨틱스, 인크. 삼중특이적 단백질 및 사용 방법
US10017560B1 (en) 2017-11-16 2018-07-10 King Saud University Nanobody against begomoviruses
KR20200104333A (ko) 2017-12-28 2020-09-03 난징 레전드 바이오테크 씨오., 엘티디. Tigit에 대한 단일-도메인 항체 및 이의 변이체
US11713353B2 (en) 2018-01-15 2023-08-01 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against PD-1
MX2020008208A (es) 2018-02-05 2020-11-09 Orionis Biosciences Inc Agentes de unión a fibroblastos y uso de estos.
EP3774917A4 (en) 2018-03-30 2022-01-19 Nanjing Legend Biotech Co., Ltd. SINGLE DOMAIN ANTIBODIES AGAINST LAG-3 AND USES THEREOF
GB2576914A (en) 2018-09-06 2020-03-11 Kymab Ltd Antigen-binding molecules comprising unpaired variable domains produced in mammals
JP7425049B2 (ja) 2018-09-25 2024-01-30 ハープーン セラピューティクス，インク． Ｄｌｌ３結合タンパク質および使用方法
JP2022533957A (ja) 2019-05-14 2022-07-27 ハープーン セラピューティクス，インク． ＥｐＣＡＭ結合タンパク質および使用方法
US20220259329A1 (en) 2019-06-07 2022-08-18 Amgen Inc. Bispecific binding constructs
CN112574308A (zh) 2019-09-30 2021-03-30 和铂医药(苏州)有限公司 靶向bcma的抗体、双特异性抗体及其用途
AU2021224851A1 (en) 2020-02-21 2022-09-15 Harpoon Therapeutics, Inc. FLT3 binding proteins and methods of use
EP4161969A1 (en) 2020-06-04 2023-04-12 Amgen Inc. Bispecific binding constructs
CN114729053B (zh) 2020-06-30 2022-10-18 和铂医药(苏州)有限公司 一种4-1bb结合蛋白及其应用
US20230270086A1 (en) * 2020-07-13 2023-08-31 Kisoji Biotechnology Inc. Transgenic animals expressing heavy chain antibodies
KR20230117397A (ko) 2020-12-03 2023-08-08 암젠 인크 다중 결합 도메인을 갖는 분자
WO2022156908A1 (en) 2021-01-25 2022-07-28 Vrije Universiteit Brussel Method for preparing a lyophilized composition
WO2022157373A1 (en) 2021-01-25 2022-07-28 Vrije Universiteit Brussel Compositions and kits for in vivo imaging of cardiac sarcoidosis
WO2022156907A1 (en) 2021-01-25 2022-07-28 Vrije Universiteit Brussel Method and kit for labeling a biomolecule with one or more detectable labels, including a radiolabel
CN117321076A (zh) 2021-02-19 2023-12-29 美国卫生及公众服务部代表 中和SARS-CoV-2的单结构域抗体
EP4323398A1 (en) 2021-04-16 2024-02-21 Bio-Techne Corporation Camelid anti-severe acute respiratory syndrome coronavirus antibodies
EP4349867A1 (en) 2021-05-28 2024-04-10 Harbour Biomed (Shanghai) Co., Ltd Specific binding protein targeting pd-l1 and cd73
TW202313690A (zh) 2021-08-18 2023-04-01 大陸商和鉑醫藥（上海）有限責任公司 一種抗b7-h4抗體及其製備方法和應用
WO2023057508A1 (en) 2021-10-05 2023-04-13 Vrije Universiteit Brussel Fluorescently labeled immunoglobulin single variable domai ns
WO2023170553A1 (en) 2022-03-07 2023-09-14 Takeda Pharmaceutical Company Limited Affinity chromatographic production of clinical human igg products
EP4349374A1 (en) 2022-10-05 2024-04-10 Vrije Universiteit Brussel Anti-urokinase plasminogen activator receptor immunoglobulin single variable domains

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
KR0184860B1 (ko) 1988-11-11 1999-04-01 메디칼 리써어치 카운실 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법)
US5874299A (en) * 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5827690A (en) * 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
ID26964A (id) * 1998-02-19 2001-02-22 Xcyte Therapies Inc Komposisi dan metode untuk pengaturan pengaktifan limfosit
US6833268B1 (en) * 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
EA013564B1 (ru) 2000-08-03 2010-06-30 Терапеутик Хьюман Поликлоналз Инк. Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция
JP3804432B2 (ja) 2000-10-17 2006-08-02 住友電装株式会社 検査ユニットおよびそれを用いたコネクタ検査装置
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
KR100882030B1 (ko) 2000-11-17 2009-02-09 교와 핫꼬 기린 가부시키가이샤 클로닝된 트랜스제닉 유제류에서 이종 (사람)면역글로블린의 발현
AU2002251913A1 (en) * 2001-02-02 2002-08-19 Millennium Pharmaceuticals, Inc. Hybrid antibodies and uses thereof
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
JP3939160B2 (ja) * 2001-05-25 2007-07-04 独立行政法人科学技術振興機構 腎臓における外来遺伝子発現方法
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
KR20050000558A (ko) 2002-05-17 2005-01-05 헤마테크, 엘엘씨 인간 항체를 제조할 수 있는 트랜스제닉 유제동물
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
JP5184374B2 (ja) * 2006-01-25 2013-04-17 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム 対立遺伝子排除

Also Published As

Publication number Publication date
EP1414858A2 (en) 2004-05-06
JP2010013479A (ja) 2010-01-21
MXPA03009785A (es) 2005-03-07
US20140033335A1 (en) 2014-01-30
MXPA03009776A (es) 2005-03-07
US8507748B2 (en) 2013-08-13
US20040142432A1 (en) 2004-07-22
PT1414858E (pt) 2007-05-31
WO2002085945A3 (en) 2003-03-06
CY1107669T1 (el) 2013-04-18
CA2445255A1 (en) 2002-10-31
DE60219321T2 (de) 2008-03-20
EP1381630A2 (en) 2004-01-21
US20140037616A1 (en) 2014-02-06
WO2002085944A2 (en) 2002-10-31
AU2002256866B2 (en) 2007-06-21
US20040137570A1 (en) 2004-07-15
JP2005503128A (ja) 2005-02-03
US20110004948A1 (en) 2011-01-06
DK1414858T3 (da) 2007-07-09
BR0209207A (pt) 2005-02-09
DE60219321D1 (de) 2007-05-16
CA2445253A1 (en) 2002-10-31
EP1414858B1 (en) 2007-04-04
ATE358730T1 (de) 2007-04-15
CN1520424A (zh) 2004-08-11
CN1518559A (zh) 2004-08-04
US20110004949A1 (en) 2011-01-06
GB0110029D0 (en) 2001-06-13
ES2284863T3 (es) 2007-11-16
JP4418159B2 (ja) 2010-02-17
CA2445253C (en) 2012-04-10
JP2005503129A (ja) 2005-02-03
CN1520424B (zh) 2012-09-05
US8502014B2 (en) 2013-08-06
WO2002085944A3 (en) 2004-03-04
WO2002085945A2 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
BR0209204A (pt) Imunoglobulina 1
PT97034A (pt) Processo para a producao de moleculas de ligacao ao antigenio cd25
WO2004016769A3 (en) Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof
ES2440825T1 (es) Inmunoglobulinas humanizadas y su producción y uso
PE20030846A1 (es) Anticuerpos para cd40
CA2306181A1 (en) Viral clearance process
DE69229477T2 (de) Methoden zur Herstellung humanisierter Antikörper
CO4480042A1 (es) Anticuerpo monoclonal anti alfa-v-integrinas
WO2003057857A3 (en) Antibodies directed to pdgfd and uses thereof
DK0865448T4 (da) Apoptose induceret af monoklonalt antistof anti-Her2
WO2004070010A3 (en) A method for generating high affinity antibodies
WO2001090192A3 (en) Bispecific immunoglobulin-like antigen binding proteins and method of production
WO2004020579A3 (en) Method of humanizing immune system molecules
ITFI930246A0 (it) Anticorpo monoclonale bispecifico anti-cd3/anti-egfr,processo per la produzione e suo uso.
BR9706236A (pt) Processo para preparar um anticorpo monoclonal contra um antigeno de superfície de célula anticorpo monoclonal compposição farmacêutica e reagente diagnóstico
BR0312808A (pt) Proteìna de fusão igg fc/hiv-gp120/c3d
CA2379901A1 (en) Prion and viral clearance process
AU2003283240A1 (en) Antibody for isolating and/or identifying mesenchymal stem cells and method for isolating and/or identifying mesenchymal stem cells
DE69733626D1 (de) Monoklonale Antikörper gegen Detergenzien und ihren Degradationsprodukte, und deren Verwendung in Immuntests
CN115494232B (zh) 4,4-二甲基噁唑啉在制备含辣根过氧化物酶的试剂中的应用
EP0889054A3 (de) Antikörper 67D2 gegen CD164
ATE382639T1 (de) Anti-humane thymidylat-synthase monoklonale antikörper und hybridomazellen zu deren herstellung
FI940684A (fi) Menetelmä Streptococcus suis -bakteerin adhesiiniproteiinin ja sen vasta-aineen valmistamiseksi

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 6A., 7A. E 8A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2060 DE 29/06/2010.